The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics.
Asthma is a chronic disease that may cause remodeling of the airways. We aimed to observe the effects of the combined use of inhaled budesonide and formoterol on both the reversibility of remodeling and structural changes in the airways. Thirty-six male patients (age range, 20-31) with mild-to-moderate persistent asthma were given inhaled formoterol and budesonide treatment for three months. Bronchial diameter (BD) and bronchial wall thickness (BWT), as measured by high-resolution computerized tomography, and reticular basement membrane thickness (RBMT), assessed in bronchoscopic biopsy specimens, were compared with pretreatment findings. Twenty-two age-matched male controls were also enrolled. BDs of the patients were significantly smaller than in the controls, whereas BWT and RBMT were greater. After three months BWT and RBMT of the subsegmental airways significantly decreased and BD increased. There was a prominent eosinophilic and lymphocytic infiltration in the bronchial mucosa of the asthmatics, and the eosinophilic infiltration significantly improved with treatment. Both serum total IgE and eosinophil counts were related to eosinophilic infiltration in the biopsy samples (r = 0.494 and r = 0.463, respectively). FEV(1) was positively correlated with the diameters of the segmental and subsegmental airways (r = 0.491 and r = 0.265, respectively) and negatively correlated with BWT of the subsegmental airways (r = -0.293) and with the RBMT of both the segmental and subsegmental airways (r = -0.597 and r = -0.590, respectively). We suggest that treatment with inhaled formoterol and budesonide may reverse increased RBMT and BWT as part of remodeling in patients with asthma.
Capraz
Firuz
F
GATA Camlica Gogus Hastaliklari Hastanesi, Acibadem Caddesi, Uskudar, Istanbul, 34660, Turkey.
Kunter
Erdogan
E
Cermik
Hakan
H
Ilvan
Ahmet
A
Pocan
Suheyl
S
D000280:Administration, Inhalation; D000328:Adult; D001249:Asthma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D001485:Basement Membrane / Q000000981:diagnostic imaging / Q000473:pathology; D001706:Biopsy; D001980:Bronchi / Q000473:pathology*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001995:Bronchography; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005541:Forced Expiratory Volume / Q000502:physiology; D000068759:Formoterol Fumarate; D006801:Humans; D020545:Respiratory Mucosa / Q000000981:diagnostic imaging / Q000473:pathology; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D001993:Bronchodilator Agents; D004983:Ethanolamines; D019819:Budesonide; D000068759:Formoterol Fumarate